Cambridge Antibody Technology Company Profile

19:56 EDT 21st September 2018 | BioPortfolio

Cambridge Antibody Technology (CAT) is a biopharmaceutical company committed to developing human monoclonal antibody therapeutics to bring improvements to seriously ill patients' lives.CAT has strong financial foundations, good medium term prospects and significant opportunities for growth in the longer term.


Milstein BuildingGranta Park
United Kingdom


Phone: 44 (0)1223 471 471
Fax: 44 (0)1223 471 472

News Articles [961 Associated News Articles listed on BioPortfolio]

Could a new antibody screening method lead to better drugs?

Antibody proteins have been the fastest-growing class of approved drugs over the last two decades, but current antibody drug discovery...Read More... The post Could a new antibody screening method lea...

IONTAS Celebrates 5 Years of Antibody Discovery

Attributes ongoing success to scientific ethos, project management, and innovative research programs IONTAS Limited (IONTAS), a leader in the discovery and optimisation of ...

Cambridge Enterprise: How Apollo Therapeutics is driving forward therapeutic innovation.

Iain Thomas, Head of Life Sciences at Cambridge University’s technology transfer arm, discusses the recent launch of Apollo Therapeutics, an ambitious collaboration between AstraZeneca, GlaxoSmithK...

Cambridge Consultants, Exact Imaging to apply AI technology to detect prostate cancer

Cambridge Consultants is applying deep learning to high-resolution micro-ultrasound imaging to detect suspicious regions of tissue, enabling urologists to use additional data in their biopsy protocol....

Elderly patients would like technology to help with day-to-day medicine taking

Over 65s say they would find technology to help them take their medications helpful, but need the technology to be familiar, accessible and easy to use, according to research by Queen Mary University ...

AdipoGen Life Sciences anti-α-Tubulin, recombinant antibodies

AdipoGen Life Sciences’ anti-α-Tubulin monoclonal antibodies (recombinant) are composed of human variable regions (VH and VL) (λ-chain) of immunoglobulin fused to the human lgG2 Fc domain. anti-...

ProBioGen & Surface Oncology sign second antibody development project

German service and technology provider, ProBioGen, and immune-oncology company, Surface Oncology, have signed a second antibody development project for the development and manufacture of another antib...

F-star, John Haurum, CEO:Designing and developing bispecific antibody products to improve the treatment of cancer.

In this episode of PharmaTelevision News Review, filmed at BIO Europe 2013, Vienna, Paul Larsmon speaks to John Haurum, CEO of F-star. They discuss the formation of the new asset centric vehicle, F-st...

PubMed Articles [1770 Associated PubMed Articles listed on BioPortfolio]

The Cambridge Social History of Modern Ireland : Edited by E.F. Biagini and M.E. Daly, Cambridge, United Kingdom and New York, NY: Cambridge University Press, 2017.

Measuring Antibody-Antigen Binding Kinetics Using Surface Plasmon Resonance.

Surface plasmon resonance (SPR) is now widely embraced as a technology for monitoring a diverse range of protein-protein interactions and is considered almost de rigueur for characterizing antibody-an...

Selection of Antibody Fragments by Yeast Display.

The critical need for renewable, high-quality affinity reagents in biological research, as well as for diagnostic and therapeutic applications, has required the development of new platforms of discove...

DENIS NOBLE, Dance to the Tune of Life-Biological Relativity, Cambridge: Cambridge University Press, December 2016, 302 pp., £ 17.99.

Significant Drying Time Reduction using Microwave-Assisted Freeze-Drying for a Monoclonal Antibody.

Microwave-assisted freeze-drying is a rapid drying process well-known in food technology. However, little is known about its application to biologicals. In this study, we investigated the applicabilit...

Clinical Trials [3064 Associated Clinical Trials listed on BioPortfolio]

Weight Loss for Obese Individuals With Gout

This study evaluates effect of weight loss in a group of obese patients with gouty arthritis. The study is a randomised group trial where half the patients receive intensive weight loss in...

Analysis of Biopsies With Antibody Mediated Rejection According to the Therapy Response

In adult kidney transplant recipients a therapy-responder and non-responder phenotype by antibody mediated rejection will be precisely defined according to clinical and histological charac...

User Evaluation of the Peristomal Skin Condition in Ostomates Using ConvaTec Moldable Technology™

The primary aim of this study is to demonstrate the maintenance of healthy peri-stomal skin over a two month period in subjects who use ConvaTec Moldable Technology™ Skin Barriers as par...

JCV Antibody Program (STRATIFY-1)

Study conducted to define the prevalence of Serum JC Antibody in relapsing MS patients receiving Tysabri or being considered for such treatment. Analytically validate the JCV antibody ass...

Expanded Access Study of Iodine-131 Anti-B1 Antibody

The primary objective of this study is to make Iodine-131 Anti-B1 Antibody more broadly available to patients. Secondary endpoints of the study will be to obtain additional information on...

Companies [1237 Associated Companies listed on BioPortfolio]

Cambridge Antibody Technology

Cambridge Antibody Technology (CAT) is a biopharmaceutical company committed to developing human monoclonal antibody therapeutics to bring improvements to seriously ill patients' lives.CAT has strong ...

Granta Park Ltd

Granta Park has established itself as the leading research park in the Cambridge sub-region. Concentrating on the life sciences it has attracted many of the foremost businesses in the field, including...

Cambridge Antibody Technology Group plc

The foundation of CAT's business is its unique antibody technologies, which it continues to develop and exploit. Based on this, CAT has established a position as a world leader, exploiting the charact...

Domantis Inc

Domantis Limited was launched in December 2000 by Sir Gregory Winter and Dr Ian Tomlinson of the MRC–LMB with the backing of the MRC and MVM Limited to commercialise Domain Antibody products. To dat...

Zenyth Therapeutics Limited

Zenyth Therapeutics Limited (Zenyth) is a public listed (ASX: ZTL) Australian biotechnology company primarily focused on the development and commercialisation of antibody-based therapies in the areas ...

More Information about "Cambridge Antibody Technology" on BioPortfolio

We have published hundreds of Cambridge Antibody Technology news stories on BioPortfolio along with dozens of Cambridge Antibody Technology Clinical Trials and PubMed Articles about Cambridge Antibody Technology for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cambridge Antibody Technology Companies in our database. You can also find out about relevant Cambridge Antibody Technology Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record